Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Tetanus Toxoid
Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Tetanus Toxoid: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Streptococcus Pneumoniae Polysaccharide Conjugated To Tetanus Toxoid.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Pembrolizumab — 26 days.
Chemical Properties
Type: Pembrolizumab — Antibody; Streptococcus Pneumoniae Polysaccharide Conjugated To Tetanus Toxoid — Vaccine component.